

# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	11	9.9	110.9	(55.3-198.4)	Female	0	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.7	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	13.3	97.5	(51.9-166.7)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.7	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	26	42.1	61.7	(40.3-90.5)
Female	0	0.2	nc	(nc-nc)	Female	27	33.7	80.2	(52.8-116.6)
<b><u>Lung and Bronchus</u></b>									
Male	1	5.8	nc	(nc-nc)					
Female	4	5.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	37	43.0	86.0	(60.5-118.6)	Male	36	26.4	136.6	(95.7-189.1)
Female	11	15.3	72.1	(35.9-129.0)	Female	27	19.6	137.5	(90.6-200.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	7.3	150.7	(75.1-269.7)	Male	9	7.0	129.1	(58.9-245.0)
Female	4	6.1	nc	(nc-nc)	Female	9	5.5	163.3	(74.5-310.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	20	23.1	86.4	(52.8-133.5)
Female	189	148.9	127.0	(109.5-146.4)	Female	21	19.2	109.6	(67.8-167.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	5.1	nc	(nc-nc)	Male	12	15.7	76.3	(39.4-133.2)
<b><u>Colon / Rectum</u></b>					Female	7	7.5	93.4	(37.4-192.6)
Male	36	50.7	71.0	(49.7-98.3)	<b><u>Ovary</u></b>				
Female	40	50.5	79.2	(56.6-107.9)	Female	14	14.3	97.8	(53.4-164.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	10.8	46.5	(15.0-108.4)	Male	11	13.7	80.4	(40.1-143.8)
Female	5	3.2	157.8	(50.9-368.3)	Female	12	14.6	82.2	(42.4-143.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	161	153.4	105.0	(89.4-122.5)
Female	2	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	9.8	51.1	(16.5-119.2)
Male	15	21.6	69.4	(38.8-114.5)	Female	4	5.8	nc	(nc-nc)
Female	7	12.6	55.7	(22.3-114.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	3.5	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	11	7.7	143.7	(71.6-257.1)
<b><u>Leukemia</u></b>					Female	27	23.3	115.7	(76.3-168.4)
Male	21	15.1	138.9	(85.9-212.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	10.8	147.8	(84.4-240.0)	Female	29	33.6	86.2	(57.7-123.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	11.7	59.7	(23.9-123.1)	Male	480	551.1	87.1	(79.5-95.3)
Female	3	4.0	nc	(nc-nc)	Female	518	523.9	98.9	(90.5-107.8)
<b><u>Lung and Bronchus</u></b>									
Male	42	77.8	54.0	(38.9-73.0)					
Female	45	77.3	58.2	(42.4-77.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	3.7	215.0	(92.6-423.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.6	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	14	11.7	120.0	(65.6-201.4)
Female	0	0.1	nc	(nc-nc)	Female	7	10.2	68.9	(27.6-141.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.5	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	9.2	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	6	4.6	131.1	(47.9-285.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.1	116.6	(42.6-253.7)
Female	22	32.6	67.4	(42.3-102.1)	Female	1	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	7	11.3	62.2	(24.9-128.2)	<b><u>Ovary</u></b>				
Female	6	10.9	55.3	(20.2-120.3)	Female	1	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	38	30.8	123.5	(87.4-169.5)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.1	nc	(nc-nc)
Male	5	4.6	109.0	(35.1-254.3)	Female	0	1.2	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	5.7	105.1	(38.4-228.7)
Male	3	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.4	nc	(nc-nc)	Female	5	7.3	68.1	(22.0-159.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	89	117.4	75.8	(60.9-93.3)
Female	0	0.9	nc	(nc-nc)	Female	78	114.0	68.4	(54.1-85.4)
<b><u>Lung and Bronchus</u></b>									
Male	4	15.8	nc	(nc-nc)					
Female	11	15.9	69.0	(34.4-123.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Littleton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	9.4	74.3	(29.8-153.2)	Male	7	6.4	109.3	(43.8-225.2)
Female	1	4.3	nc	(nc-nc)	Female	1	5.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	33	40.0	82.5	(56.8-115.9)	Female	8	5.3	150.0	(64.6-295.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.0	nc	(nc-nc)
Male	12	11.6	103.7	(53.5-181.2)	<b><u>Ovary</u></b>				
Female	11	14.8	74.6	(37.2-133.4)	Female	2	3.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	39	37.5	104.1	(74.0-142.3)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.2	nc	(nc-nc)
Male	6	5.4	111.4	(40.7-242.4)	Female	1	1.7	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	6.3	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.2	156.1	(50.3-364.2)	Female	9	8.8	101.9	(46.5-193.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	108	130.6	82.7	(67.8-99.8)
Female	0	1.1	nc	(nc-nc)	Female	107	144.2	74.2	(60.8-89.7)
<b><u>Lung and Bronchus</u></b>									
Male	11	17.3	63.5	(31.7-113.7)					
Female	13	20.6	63.2	(33.6-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	20.6	63.1	(33.6-107.9)	Male	19	12.5	151.6	(91.2-236.8)
Female	5	7.7	65.2	(21.0-152.0)	Female	14	9.9	141.9	(77.5-238.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	5	3.3	150.7	(48.6-351.6)
Female	3	3.2	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	15	11.1	135.0	(75.5-222.7)
Female	85	73.4	115.9	(92.5-143.3)	Female	8	9.6	83.2	(35.8-164.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	3.7	nc	(nc-nc)
Male	17	24.1	70.6	(41.1-113.1)	<b><u>Ovary</u></b>				
Female	13	25.8	50.4	(26.8-86.1)	Female	8	7.2	111.5	(48.0-219.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.1	118.8	(43.4-258.5)	Male	0	6.5	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	8	7.4	108.6	(46.7-213.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	91	71.3	127.6	(102.7-156.7)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.7	nc	(nc-nc)
Male	17	10.1	168.2	(97.9-269.3)	Female	2	3.0	nc	(nc-nc)
Female	5	6.2	80.1	(25.8-187.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.9	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	11.6	86.2	(41.2-158.5)
Male	6	7.3	82.7	(30.2-180.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.7	nc	(nc-nc)	Female	13	16.4	79.1	(42.1-135.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.5	nc	(nc-nc)	Male	244	260.6	93.6	(82.3-106.1)
Female	1	2.0	nc	(nc-nc)	Female	238	261.7	90.9	(79.8-103.3)
<b><u>Lung and Bronchus</u></b>									
Male	18	36.7	49.1	(29.1-77.6)					
Female	26	38.2	68.1	(44.5-99.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	83	83.8	99.1	(78.9-122.8)	Male	25	59.7	41.9	(27.1-61.9)
Female	42	33.8	124.1	(89.4-167.8)	Female	29	51.8	55.9	(37.5-80.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	19.0	84.2	(48.1-136.8)	Male	13	14.2	91.3	(48.6-156.2)
Female	17	16.5	103.3	(60.2-165.4)	Female	12	12.2	98.5	(50.8-172.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	2.5	200.3	(64.5-467.4)	Male	50	52.1	96.0	(71.2-126.5)
Female	278	349.4	79.6	(70.5-89.5)	Female	35	44.5	78.6	(54.8-109.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	21	14.6	143.4	(88.7-219.1)	Male	51	37.0	138.0	(102.7-181.4)
<b><u>Colon / Rectum</u></b>					Female	14	17.6	79.4	(43.4-133.3)
Male	122	104.5	116.8	(97.0-139.4)	<b><u>Ovary</u></b>				
Female	129	112.9	114.3	(95.4-135.8)	Female	28	34.1	82.1	(54.5-118.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	21	23.0	91.4	(56.5-139.7)	Male	25	27.5	90.9	(58.8-134.2)
Female	6	6.9	87.0	(31.8-189.3)	Female	23	32.1	71.6	(45.4-107.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	9	9.9	90.6	(41.4-172.1)	Male	254	333.1	76.3	(67.2-86.2)
Female	4	8.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	19	19.8	95.7	(57.6-149.5)
Male	50	48.9	102.2	(75.8-134.7)	Female	12	13.0	92.1	(47.5-160.9)
Female	39	29.2	133.4	(94.8-182.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	17.7	62.2	(31.0-111.4)
Male	20	13.4	148.8	(90.8-229.8)	<b><u>Thyroid</u></b>				
Female	7	4.1	170.6	(68.3-351.5)	Male	25	21.8	114.9	(74.3-169.6)
<b><u>Leukemia</u></b>					Female	70	69.4	100.9	(78.7-127.5)
Male	43	33.3	129.0	(93.4-173.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	35	26.7	131.1	(91.3-182.3)	Female	78	79.3	98.3	(77.7-122.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	51	26.2	195.0	(145.2-256.4)	Male	1203	1192.2	100.9	(95.3-106.8)
Female	12	9.3	128.7	(66.4-224.8)	Female	1156	1235.0	93.6	(88.3-99.2)
<b><u>Lung and Bronchus</u></b>									
Male	211	155.8	135.4	(117.8-155.0)					
Female	159	170.6	93.2	(79.3-108.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	27.2	80.9	(50.7-122.6)	Male	9	17.8	50.5	(23.0-95.8)
Female	8	10.4	77.1	(33.2-151.9)	Female	12	13.3	90.2	(46.6-157.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.0	118.9	(43.4-258.7)	Male	2	4.5	nc	(nc-nc)
Female	7	4.1	170.0	(68.1-350.2)	Female	3	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	9	15.5	58.2	(26.6-110.6)
Female	77	97.7	78.8	(62.2-98.5)	Female	10	13.0	77.0	(36.9-141.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.5	nc	(nc-nc)	Male	5	10.6	47.2	(15.2-110.1)
<b><u>Colon / Rectum</u></b>					Female	2	5.0	nc	(nc-nc)
Male	39	32.9	118.6	(84.3-162.2)	<b><u>Ovary</u></b>				
Female	24	34.3	70.0	(44.8-104.1)	Female	5	9.6	52.2	(16.8-121.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.0	71.2	(22.9-166.2)	Male	10	8.7	114.4	(54.8-210.4)
Female	1	2.2	nc	(nc-nc)	Female	8	9.9	80.6	(34.7-158.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	2.4	209.0	(67.3-487.6)	Male	92	101.8	90.3	(72.8-110.8)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	6.3	142.3	(64.9-270.1)
Male	14	14.4	97.1	(53.1-163.0)	Female	3	4.0	nc	(nc-nc)
Female	4	8.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	4.0	148.9	(54.4-324.2)
Male	3	4.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	1	5.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	15.8	63.3	(30.3-116.4)
Male	9	9.8	91.9	(41.9-174.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	7.4	68.0	(21.9-158.6)	Female	16	22.2	72.1	(41.2-117.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	7.7	104.5	(45.0-205.9)	Male	320	363.9	87.9	(78.6-98.1)
Female	0	2.7	nc	(nc-nc)	Female	241	351.1	68.6	(60.3-77.9)
<b><u>Lung and Bronchus</u></b>									
Male	42	49.8	84.4	(60.8-114.1)					
Female	29	52.3	55.5	(37.1-79.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	10.6	131.9	(72.1-221.4)	Male	7	7.5	93.7	(37.5-193.0)
Female	1	3.6	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	5	1.8	273.0	(88.0-637.2)
Female	3	1.7	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	40	42.5	94.1	(67.2-128.1)	Female	5	4.8	104.5	(33.7-243.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	8	13.3	60.1	(25.9-118.5)	<b><u>Ovary</u></b>				
Female	10	11.8	84.7	(40.5-155.7)	Female	4	3.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	53	42.8	123.9	(92.8-162.0)
Female	3	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.5	nc	(nc-nc)
Male	6	6.2	96.1	(35.1-209.2)	Female	1	1.3	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.6	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	7.8	76.9	(28.1-167.4)
Male	6	4.1	147.5	(53.9-321.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.7	nc	(nc-nc)	Female	12	9.6	124.4	(64.2-217.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	149	150.1	99.2	(83.9-116.5)
Female	1	1.0	nc	(nc-nc)	Female	124	139.3	89.0	(74.0-106.1)
<b><u>Lung and Bronchus</u></b>									
Male	23	19.8	116.2	(73.6-174.4)					
Female	16	19.0	84.1	(48.0-136.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	71	80.2	88.5	(69.1-111.6)	Male	42	55.0	76.4	(55.1-103.3)
Female	33	28.8	114.6	(78.9-160.9)	Female	30	44.8	67.0	(45.2-95.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	16.9	94.8	(54.2-154.0)	Male	17	13.4	126.4	(73.6-202.4)
Female	15	14.1	106.7	(59.7-176.0)	Female	11	10.4	105.5	(52.6-188.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	46	47.7	96.4	(70.6-128.6)
Female	277	309.1	89.6	(79.4-100.8)	Female	49	38.2	128.2	(94.8-169.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	12.8	93.8	(48.4-163.8)	Male	47	33.5	140.5	(103.2-186.8)
<b><u>Colon / Rectum</u></b>					Female	25	15.3	163.3	(105.7-241.1)
Male	83	98.0	84.7	(67.5-105.0)	<b><u>Ovary</u></b>				
Female	98	95.5	102.6	(83.3-125.0)	Female	34	29.7	114.3	(79.2-159.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	31	21.7	142.7	(97.0-202.6)	Male	24	26.1	91.9	(58.8-136.7)
Female	9	5.9	152.5	(69.6-289.4)	Female	28	27.2	103.0	(68.5-148.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	8.3	96.9	(41.7-191.0)	Male	293	319.9	91.6	(81.4-102.7)
Female	3	6.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	18.8	106.3	(64.9-164.2)
Male	46	45.2	101.9	(74.6-135.9)	Female	20	10.9	183.8	(112.2-283.9)
Female	30	25.6	117.4	(79.2-167.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	14.3	63.1	(28.8-119.7)
Male	14	12.7	110.2	(60.2-184.9)	<b><u>Thyroid</u></b>				
Female	3	3.6	nc	(nc-nc)	Male	8	19.0	42.0	(18.1-82.9)
<b><u>Leukemia</u></b>					Female	58	60.5	95.9	(72.8-123.9)
Male	35	30.8	113.7	(79.2-158.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	27	22.5	119.8	(78.9-174.3)	Female	82	70.4	116.5	(92.7-144.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	36	23.9	150.4	(105.3-208.2)	Male	1117	1120.8	99.7	(93.9-105.7)
Female	8	8.0	99.8	(43.0-196.6)	Female	1163	1071.9	108.5	(102.3-114.9)
<b><u>Lung and Bronchus</u></b>									
Male	174	150.0	116.0	(99.4-134.6)					
Female	198	148.5	133.3	(115.4-153.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	15.9	100.9	(57.6-163.8)	Male	18	9.8	183.2	(108.5-289.5)
Female	4	5.0	nc	(nc-nc)	Female	10	7.0	142.9	(68.4-262.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	13	8.6	150.7	(80.2-257.7)
Female	62	53.3	116.3	(89.1-149.1)	Female	8	6.4	124.1	(53.4-244.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	2.6	nc	(nc-nc)
Male	23	18.5	124.3	(78.8-186.6)	<b><u>Ovary</u></b>				
Female	20	16.2	123.1	(75.2-190.2)	Female	7	5.1	137.7	(55.2-283.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.1	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	70	58.8	119.0	(92.7-150.3)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.6	nc	(nc-nc)
Male	10	8.1	123.6	(59.2-227.3)	Female	2	1.8	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.5	nc	(nc-nc)
Male	5	2.3	213.2	(68.7-497.5)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	6	2.9	204.3	(74.6-444.6)
<b><u>Leukemia</u></b>					Female	11	8.8	124.9	(62.3-223.5)
Male	12	5.6	215.9	(111.4-377.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	3.6	197.1	(79.0-406.2)	Female	14	12.5	112.2	(61.3-188.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.4	nc	(nc-nc)	Male	224	206.8	108.3	(94.6-123.5)
Female	2	1.4	nc	(nc-nc)	Female	204	181.9	112.2	(97.3-128.7)
<b><u>Lung and Bronchus</u></b>									
Male	24	29.3	81.9	(52.5-121.9)					
Female	25	26.7	93.7	(60.6-138.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	59	52.2	112.9	(86.0-145.7)	Male	16	36.4	44.0	(25.1-71.4)
Female	32	18.7	171.0	(116.9-241.4)	Female	22	29.3	75.0	(47.0-113.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	11.1	116.6	(62.0-199.4)	Male	7	8.8	79.5	(31.8-163.7)
Female	9	9.0	100.3	(45.8-190.4)	Female	5	6.8	73.8	(23.8-172.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	28	31.5	88.9	(59.0-128.5)
Female	204	201.1	101.4	(88.0-116.4)	Female	18	24.8	72.7	(43.0-114.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	8.5	94.2	(40.6-185.6)	Male	28	22.1	126.9	(84.3-183.4)
<b><u>Colon / Rectum</u></b>					Female	7	10.0	70.2	(28.1-144.5)
Male	95	64.6	147.0	(118.9-179.7)	<b><u>Ovary</u></b>				
Female	73	61.9	117.9	(92.4-148.2)	Female	18	19.3	93.2	(55.2-147.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	19	14.1	135.2	(81.3-211.1)	Male	16	17.0	94.1	(53.7-152.8)
Female	4	3.8	nc	(nc-nc)	Female	16	17.6	90.8	(51.9-147.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	5.8	86.4	(27.8-201.6)	Male	161	204.2	78.9	(67.1-92.0)
Female	5	4.3	116.5	(37.5-271.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	19	12.3	154.5	(93.0-241.3)
Male	26	29.6	87.9	(57.4-128.7)	Female	4	7.1	nc	(nc-nc)
Female	17	16.6	102.4	(59.6-163.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	10.5	95.3	(45.6-175.2)
Male	6	8.2	73.1	(26.7-159.1)	<b><u>Thyroid</u></b>				
Female	5	2.4	211.3	(68.1-493.1)	Male	11	12.9	85.2	(42.5-152.4)
<b><u>Leukemia</u></b>					Female	45	40.2	112.0	(81.7-149.9)
Male	21	19.9	105.3	(65.2-161.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	20	14.3	139.8	(85.4-215.9)	Female	42	45.6	92.1	(66.4-124.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	29	15.8	183.0	(122.6-262.9)	Male	734	730.4	100.5	(93.4-108.0)
Female	11	5.2	211.6	(105.5-378.6)	Female	759	697.0	108.9	(101.3-116.9)
<b><u>Lung and Bronchus</u></b>									
Male	105	97.1	108.2	(88.5-131.0)					
Female	124	96.4	128.6	(107.0-153.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.2	83.5	(30.5-181.8)	Male	13	4.5	289.9	(154.2-495.8)
Female	1	2.3	nc	(nc-nc)	Female	13	3.1	418.3	(222.5-715.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	36	23.3	154.5	(108.2-213.9)	Female	3	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.1	nc	(nc-nc)
Male	9	8.5	105.5	(48.1-200.3)	<b><u>Ovary</u></b>				
Female	10	7.9	127.2	(60.9-234.0)	Female	3	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	28	26.2	106.9	(71.0-154.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	3.8	159.9	(58.4-348.0)
Male	4	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.7	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	98	93.5	104.9	(85.1-127.8)
Female	0	0.6	nc	(nc-nc)	Female	108	81.2	133.1	(109.2-160.7)
<b><u>Lung and Bronchus</u></b>									
Male	5	13.0	38.5	(12.4-89.9)					
Female	8	11.7	68.2	(29.4-134.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	16.3	79.9	(42.5-136.6)	Male	14	12.6	110.8	(60.5-185.9)
Female	5	5.6	89.2	(28.7-208.2)	Female	16	10.6	151.6	(86.6-246.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.2	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	5	3.2	154.7	(49.8-360.9)	Female	0	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	12	11.1	107.9	(55.7-188.6)
Female	83	72.7	114.2	(91.0-141.6)	Female	4	7.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	10	8.3	120.9	(57.9-222.4)
<b><u>Colon / Rectum</u></b>					Female	4	3.3	nc	(nc-nc)
Male	22	21.9	100.4	(62.9-152.0)	<b><u>Ovary</u></b>				
Female	21	19.4	108.0	(66.8-165.1)	Female	7	6.6	105.3	(42.2-216.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	4.7	191.4	(87.3-363.3)	Male	5	5.5	91.1	(29.3-212.5)
Female	0	1.1	nc	(nc-nc)	Female	9	5.3	170.7	(77.9-324.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	64	67.4	94.9	(73.1-121.2)
Female	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.1	nc	(nc-nc)
Male	11	10.7	103.2	(51.5-184.7)	Female	1	2.2	nc	(nc-nc)
Female	12	5.5	217.3	(112.2-379.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.7	133.8	(43.1-312.2)
Male	5	2.8	179.6	(57.9-419.1)	<b><u>Thyroid</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	6	5.0	120.0	(43.8-261.3)
<b><u>Leukemia</u></b>					Female	21	15.7	134.0	(82.9-204.8)
Male	10	7.1	141.6	(67.8-260.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.9	nc	(nc-nc)	Female	12	15.7	76.4	(39.4-133.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	5.7	106.1	(38.8-231.0)	Male	236	245.4	96.2	(84.3-109.2)
Female	1	1.6	nc	(nc-nc)	Female	271	235.6	115.0	(101.7-129.6)
<b><u>Lung and Bronchus</u></b>									
Male	21	30.6	68.7	(42.5-105.0)					
Female	44	29.1	151.2	(109.9-203.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	25.0	92.0	(58.3-138.1)	Male	30	16.3	183.9	(124.1-262.6)
Female	14	8.4	167.4	(91.5-280.9)	Female	26	12.0	216.2	(141.2-316.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.6	107.7	(34.7-251.2)	Male	2	4.2	nc	(nc-nc)
Female	8	3.7	215.8	(92.9-425.3)	Female	2	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	18	14.1	127.8	(75.7-202.0)
Female	109	91.6	119.0	(97.7-143.6)	Female	11	10.9	100.6	(50.2-180.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.4	nc	(nc-nc)	Male	10	10.3	97.5	(46.7-179.3)
<b><u>Colon / Rectum</u></b>					Female	3	4.4	nc	(nc-nc)
Male	33	30.2	109.2	(75.2-153.4)	<b><u>Ovary</u></b>				
Female	28	27.4	102.3	(68.0-147.9)	Female	11	8.6	128.0	(63.8-229.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	6.7	nc	(nc-nc)	Male	11	8.2	134.9	(67.3-241.4)
Female	2	1.7	nc	(nc-nc)	Female	12	7.8	153.3	(79.1-267.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	105	99.4	105.6	(86.4-127.8)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	5.8	nc	(nc-nc)
Male	10	13.7	72.9	(34.9-134.1)	Female	4	3.1	nc	(nc-nc)
Female	6	7.5	80.2	(29.3-174.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.5	nc	(nc-nc)
Male	0	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	5	5.1	97.1	(31.3-226.7)
<b><u>Leukemia</u></b>					Female	11	15.5	70.8	(35.3-126.6)
Male	9	9.1	99.4	(45.4-188.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	6.1	147.5	(67.3-280.0)	Female	16	21.1	75.9	(43.3-123.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.4	81.2	(29.7-176.8)	Male	343	340.7	100.7	(90.3-111.9)
Female	7	2.3	301.4	(120.7-621.0)	Female	360	308.8	116.6	(104.9-129.3)
<b><u>Lung and Bronchus</u></b>									
Male	29	46.5	62.4	(41.8-89.6)					
Female	40	44.1	90.6	(64.8-123.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.7	78.2	(28.6-170.3)	Male	6	4.7	127.6	(46.6-277.8)
Female	5	3.2	158.5	(51.1-370.0)	Female	4	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	29	26.4	110.0	(73.7-158.0)	Female	4	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.4	nc	(nc-nc)
Male	3	9.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	8	11.0	72.8	(31.3-143.4)	Female	4	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	36	29.1	123.6	(86.6-171.2)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	0	3.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.8	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.2	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	94	100.1	93.9	(75.9-114.9)
Female	2	0.8	nc	(nc-nc)	Female	90	99.1	90.8	(73.0-111.6)
<b><u>Lung and Bronchus</u></b>									
Male	13	14.0	92.9	(49.4-158.8)					
Female	10	14.2	70.4	(33.7-129.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	45	35.2	127.8	(93.2-171.0)	Male	18	25.2	71.6	(42.4-113.1)
Female	13	13.9	93.4	(49.7-159.8)	Female	13	21.1	61.6	(32.8-105.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.6	78.7	(28.7-171.4)	Male	4	6.0	nc	(nc-nc)
Female	6	6.5	91.6	(33.5-199.5)	Female	4	5.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	26	21.5	120.8	(78.9-177.0)
Female	122	148.5	82.2	(68.2-98.1)	Female	17	18.3	93.1	(54.2-149.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	15	6.0	248.6	(139.0-410.0)	Male	16	15.5	103.5	(59.1-168.1)
<b><u>Colon / Rectum</u></b>					Female	7	7.3	95.9	(38.4-197.6)
Male	34	44.0	77.3	(53.5-108.0)	<b><u>Ovary</u></b>				
Female	40	46.2	86.6	(61.8-117.9)	Female	16	14.2	112.9	(64.5-183.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	9.6	104.5	(50.0-192.2)	Male	7	11.6	60.3	(24.2-124.3)
Female	5	2.9	175.2	(56.5-408.8)	Female	14	13.1	106.5	(58.2-178.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	3.7	216.7	(93.3-426.9)	Male	130	138.1	94.1	(78.6-111.7)
Female	5	2.9	175.3	(56.5-409.0)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	8.4	118.6	(56.8-218.1)
Male	27	20.8	129.8	(85.5-188.8)	Female	3	5.3	nc	(nc-nc)
Female	9	12.3	73.4	(33.5-139.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	6.7	74.3	(24.0-173.5)
Male	2	5.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	12	9.2	131.1	(67.7-229.0)
<b><u>Leukemia</u></b>					Female	32	28.2	113.5	(77.6-160.2)
Male	17	13.4	126.4	(73.6-202.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	10.7	74.4	(32.1-146.7)	Female	34	33.5	101.5	(70.3-141.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	10.8	139.0	(77.7-229.2)	Male	484	496.5	97.5	(89.0-106.6)
Female	4	3.8	nc	(nc-nc)	Female	498	513.2	97.0	(88.7-105.9)
<b><u>Lung and Bronchus</u></b>									
Male	59	65.7	89.8	(68.4-115.9)					
Female	81	71.6	113.1	(89.8-140.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	25.5	117.7	(79.4-168.0)	Male	35	18.1	193.3	(134.6-268.8)
Female	13	8.9	146.0	(77.7-249.7)	Female	18	14.0	128.8	(76.3-203.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	5	4.5	111.0	(35.8-259.1)
Female	5	4.2	118.8	(38.3-277.1)	Female	6	3.3	182.7	(66.7-397.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	0.8	nc	(nc-nc)	Male	19	15.5	123.0	(74.0-192.0)
Female	122	105.3	115.8	(96.2-138.3)	Female	15	11.9	125.6	(70.3-207.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.1	123.3	(39.7-287.8)	Male	9	11.9	75.8	(34.6-143.9)
<b><u>Colon / Rectum</u></b>					Female	6	5.0	119.9	(43.8-261.0)
Male	39	32.1	121.4	(86.3-166.0)	<b><u>Ovary</u></b>				
Female	33	29.5	111.8	(76.9-157.0)	Female	12	9.8	122.4	(63.2-213.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	7.5	120.5	(55.0-228.8)	Male	5	8.6	57.9	(18.7-135.1)
Female	2	1.8	nc	(nc-nc)	Female	10	8.3	120.3	(57.6-221.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	135	113.1	119.3	(100.0-141.2)
Female	3	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.1	nc	(nc-nc)
Male	15	15.5	96.9	(54.2-159.8)	Female	4	3.3	nc	(nc-nc)
Female	3	8.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	3.5	200.4	(80.3-412.9)
Male	2	4.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	1	6.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	20	19.0	105.4	(64.4-162.8)
Male	11	9.7	113.8	(56.7-203.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.7	89.4	(32.6-194.5)	Female	21	24.4	86.0	(53.2-131.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	8.4	59.6	(19.2-139.1)	Male	424	374.5	113.2	(102.7-124.5)
Female	1	2.5	nc	(nc-nc)	Female	405	345.9	117.1	(106.0-129.1)
<b><u>Lung and Bronchus</u></b>									
Male	58	49.5	117.2	(89.0-151.5)					
Female	64	47.0	136.1	(104.8-173.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	24.1	132.8	(90.8-187.5)	Male	21	14.3	146.8	(90.8-224.4)
Female	9	8.2	110.2	(50.3-209.3)	Female	9	9.9	91.3	(41.7-173.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	5	3.9	129.7	(41.8-302.7)
Female	3	3.1	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	13	12.4	105.1	(55.9-179.8)
Female	91	75.3	120.9	(97.3-148.4)	Female	5	10.1	49.7	(16.0-115.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	8	8.2	97.2	(41.8-191.5)
<b><u>Colon / Rectum</u></b>					Female	5	3.9	128.8	(41.5-300.6)
Male	25	27.5	90.9	(58.8-134.2)	<b><u>Ovary</u></b>				
Female	24	25.3	94.8	(60.7-141.0)	Female	6	7.4	81.3	(29.7-176.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	6.0	117.2	(46.9-241.4)	Male	9	7.6	118.0	(53.8-224.0)
Female	0	1.7	nc	(nc-nc)	Female	8	7.7	104.4	(45.0-205.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	95	87.1	109.0	(88.2-133.3)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	5.4	148.5	(63.9-292.6)
Male	13	11.6	112.0	(59.6-191.5)	Female	1	2.9	nc	(nc-nc)
Female	7	6.8	103.4	(41.4-213.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	1.8	380.5	(152.4-784.0)
Male	2	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	11.2	62.7	(25.1-129.2)
Male	9	8.0	111.8	(51.0-212.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.5	90.5	(29.2-211.3)	Female	16	17.9	89.2	(50.9-144.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.2	nc	(nc-nc)	Male	322	304.6	105.7	(94.5-117.9)
Female	4	2.1	nc	(nc-nc)	Female	272	271.7	100.1	(88.6-112.7)
<b><u>Lung and Bronchus</u></b>									
Male	32	44.0	72.7	(49.7-102.6)					
Female	48	43.8	109.7	(80.9-145.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.9	73.3	(31.5-144.4)	Male	9	6.7	134.0	(61.1-254.4)
Female	2	3.2	nc	(nc-nc)	Female	5	4.2	117.7	(37.9-274.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.8	103.9	(37.9-226.1)
Female	29	32.9	88.0	(58.9-126.4)	Female	2	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	5	4.1	122.2	(39.4-285.1)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	8	12.8	62.7	(27.0-123.5)	<b><u>Ovary</u></b>				
Female	17	10.4	162.9	(94.8-260.9)	Female	4	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	39	41.3	94.4	(67.1-129.0)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.5	nc	(nc-nc)
Male	1	5.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	5.1	175.9	(80.2-333.8)
Male	5	3.6	138.3	(44.6-322.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	6	7.9	75.9	(27.7-165.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	113	142.1	79.5	(65.5-95.6)
Female	0	0.9	nc	(nc-nc)	Female	109	114.0	95.6	(78.5-115.4)
<b><u>Lung and Bronchus</u></b>									
Male	11	20.2	54.5	(27.2-97.5)					
Female	14	16.8	83.2	(45.4-139.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	11.1	81.1	(37.0-153.9)	Male	13	7.2	179.8	(95.6-307.4)
Female	2	3.6	nc	(nc-nc)	Female	11	5.9	188.0	(93.7-336.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	9	6.4	139.9	(63.9-265.7)
Female	46	40.6	113.2	(82.9-151.0)	Female	4	4.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.0	nc	(nc-nc)
Male	15	13.3	112.4	(62.9-185.4)	<b><u>Ovary</u></b>				
Female	14	12.5	112.0	(61.2-187.9)	Female	7	3.8	181.8	(72.9-374.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.5	144.6	(46.6-337.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	35	39.0	89.6	(62.4-124.7)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.6	nc	(nc-nc)
Male	3	5.8	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	6	2.4	254.9	(93.1-554.8)
<b><u>Leukemia</u></b>					Female	7	8.0	87.2	(34.9-179.6)
Male	0	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.9	nc	(nc-nc)	Female	12	9.1	131.9	(68.1-230.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	143	145.8	98.1	(82.7-115.5)
Female	2	1.0	nc	(nc-nc)	Female	161	138.2	116.5	(99.2-136.0)
<b><u>Lung and Bronchus</u></b>									
Male	17	20.0	85.1	(49.5-136.2)					
Female	21	18.1	115.8	(71.7-177.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	11.5	95.7	(47.7-171.2)	Male	14	8.0	174.7	(95.4-293.1)
Female	11	4.0	275.3	(137.3-492.7)	Female	7	6.4	109.5	(43.9-225.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	7.1	70.7	(22.8-165.1)
Female	66	47.7	138.3	(106.9-175.9)	Female	2	5.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.2	nc	(nc-nc)
Male	25	14.7	170.3	(110.2-251.5)	<b><u>Ovary</u></b>				
Female	16	14.0	114.4	(65.4-185.8)	Female	3	4.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	6	3.8	157.2	(57.4-342.3)
Female	0	0.8	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	58	45.8	126.6	(96.1-163.6)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.8	nc	(nc-nc)
Male	3	6.8	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.8	113.9	(54.5-209.5)
Male	6	4.5	134.1	(49.0-291.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.2	nc	(nc-nc)	Female	13	10.5	124.4	(66.2-212.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	185	162.6	113.8	(98.0-131.4)
Female	2	1.1	nc	(nc-nc)	Female	170	156.3	108.8	(93.0-126.4)
<b><u>Lung and Bronchus</u></b>									
Male	20	21.5	93.2	(56.9-143.9)					
Female	15	20.0	74.9	(41.9-123.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	74	64.6	114.5	(89.9-143.7)	Male	43	40.5	106.2	(76.9-143.1)
Female	38	25.9	146.8	(103.8-201.4)	Female	35	34.5	101.3	(70.6-140.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	11.5	69.7	(30.0-137.3)	Male	5	10.4	48.1	(15.5-112.2)
Female	10	10.8	92.6	(44.3-170.3)	Female	9	9.2	98.0	(44.7-186.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	33	35.4	93.2	(64.1-130.9)
Female	262	240.6	108.9	(96.1-122.9)	Female	26	32.5	79.9	(52.2-117.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	9.4	96.2	(43.9-182.7)	Male	28	22.8	122.7	(81.5-177.4)
<b><u>Colon / Rectum</u></b>					Female	12	12.6	95.3	(49.2-166.6)
Male	94	75.6	124.4	(100.5-152.2)	<b><u>Ovary</u></b>				
Female	75	84.7	88.5	(69.6-110.9)	Female	24	23.9	100.4	(64.3-149.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	15.7	82.8	(44.0-141.6)	Male	20	20.4	98.2	(59.9-151.6)
Female	4	5.3	nc	(nc-nc)	Female	17	24.6	69.0	(40.2-110.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	5.6	125.1	(50.1-257.9)	Male	170	221.2	76.9	(65.7-89.3)
Female	4	4.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	14.6	82.3	(42.5-143.7)
Male	39	31.7	123.0	(87.5-168.1)	Female	8	10.0	80.2	(34.5-158.0)
Female	18	20.8	86.4	(51.2-136.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	9.7	51.5	(16.6-120.3)
Male	12	9.0	133.5	(68.9-233.2)	<b><u>Thyroid</u></b>				
Female	2	2.9	nc	(nc-nc)	Male	13	12.6	102.9	(54.7-176.0)
<b><u>Leukemia</u></b>					Female	54	43.0	125.6	(94.4-163.9)
Male	20	23.0	86.8	(53.0-134.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	24	18.7	128.5	(82.3-191.2)	Female	51	55.2	92.4	(68.8-121.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	21	16.8	124.6	(77.1-190.5)	Male	799	823.7	97.0	(90.4-104.0)
Female	13	6.8	191.0	(101.6-326.6)	Female	886	877.2	101.0	(94.5-107.9)
<b><u>Lung and Bronchus</u></b>									
Male	111	115.1	96.5	(79.4-116.2)					
Female	122	128.2	95.1	(79.0-113.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	11.8	85.0	(40.7-156.3)	Male	4	8.2	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	8	6.6	120.3	(51.8-237.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	7.2	194.3	(106.2-326.1)
Female	33	47.2	69.9	(48.1-98.1)	Female	8	5.6	143.0	(61.6-281.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.3	nc	(nc-nc)
Male	14	14.7	95.0	(51.9-159.4)	<b><u>Ovary</u></b>				
Female	21	14.8	141.8	(87.8-216.8)	Female	6	4.4	134.9	(49.3-293.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.2	154.6	(49.8-360.8)	Male	6	3.9	154.7	(56.5-336.8)
Female	1	0.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	54	46.7	115.7	(86.9-151.0)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.8	nc	(nc-nc)
Male	5	6.9	72.9	(23.5-170.1)	Female	1	1.7	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	9.0	111.3	(53.3-204.8)
Male	4	4.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.4	nc	(nc-nc)	Female	6	10.2	58.7	(21.4-127.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	160	165.4	96.7	(82.3-112.9)
Female	0	1.2	nc	(nc-nc)	Female	142	159.3	89.1	(75.1-105.1)
<b><u>Lung and Bronchus</u></b>									
Male	16	21.7	73.8	(42.1-119.8)					
Female	25	20.4	122.4	(79.2-180.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	37	33.6	110.2	(77.6-151.9)	Male	29	21.1	137.2	(91.9-197.1)
Female	17	11.7	145.5	(84.7-233.0)	Female	24	16.1	149.0	(95.4-221.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	6.0	183.7	(91.6-328.6)	Male	3	5.5	nc	(nc-nc)
Female	5	5.0	100.4	(32.4-234.4)	Female	4	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	21	18.4	113.9	(70.5-174.2)
Female	124	116.9	106.1	(88.3-126.5)	Female	18	14.9	121.1	(71.7-191.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.4	nc	(nc-nc)	Male	13	12.3	106.0	(56.4-181.3)
<b><u>Colon / Rectum</u></b>					Female	4	5.8	nc	(nc-nc)
Male	34	40.0	85.1	(58.9-118.9)	<b><u>Ovary</u></b>				
Female	51	38.5	132.3	(98.5-174.0)	Female	13	11.2	115.9	(61.6-198.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	8.3	72.4	(26.4-157.5)	Male	7	10.7	65.5	(26.2-134.9)
Female	5	2.4	206.5	(66.5-481.8)	Female	14	11.1	125.8	(68.7-211.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	102	117.7	86.7	(70.7-105.2)
Female	3	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	7.7	156.1	(80.6-272.7)
Male	24	16.9	141.9	(90.9-211.1)	Female	5	4.4	112.7	(36.3-263.1)
Female	10	9.9	101.3	(48.5-186.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	4.0	nc	(nc-nc)
Male	8	4.8	167.6	(72.2-330.2)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	9	6.5	138.0	(63.0-261.9)
<b><u>Leukemia</u></b>					Female	20	20.1	99.5	(60.7-153.6)
Male	16	12.1	131.9	(75.4-214.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	8.6	nc	(nc-nc)	Female	31	26.3	117.7	(80.0-167.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	8.9	56.1	(18.1-130.9)	Male	427	432.1	98.8	(89.7-108.6)
Female	1	3.1	nc	(nc-nc)	Female	445	410.8	108.3	(98.5-118.9)
<b><u>Lung and Bronchus</u></b>									
Male	61	60.0	101.6	(77.7-130.5)					
Female	57	59.8	95.2	(72.1-123.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.1	116.8	(42.7-254.3)	Male	2	3.7	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	27	21.1	127.8	(84.2-185.9)	Female	4	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	5	6.8	73.3	(23.6-171.1)	<b><u>Ovary</u></b>				
Female	7	5.8	120.5	(48.3-248.2)	Female	3	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	36	22.1	163.1	(114.2-225.8)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.3	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.2	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.4	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	78	75.5	103.4	(81.7-129.0)
Female	0	0.5	nc	(nc-nc)	Female	71	68.7	103.4	(80.8-130.5)
<b><u>Lung and Bronchus</u></b>									
Male	7	9.6	72.7	(29.1-149.8)					
Female	7	8.7	80.7	(32.3-166.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.2	111.3	(47.9-219.3)	Male	3	4.9	nc	(nc-nc)
Female	5	2.3	215.9	(69.6-503.9)	Female	5	3.6	138.9	(44.8-324.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	30	26.2	114.4	(77.2-163.3)	Female	3	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	6	8.8	67.9	(24.8-147.9)	<b><u>Ovary</u></b>				
Female	9	7.8	116.0	(53.0-220.3)	Female	3	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	26	29.0	89.8	(58.6-131.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.8	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	8	5.9	135.0	(58.1-266.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	91	100.2	90.8	(73.1-111.5)
Female	0	0.7	nc	(nc-nc)	Female	95	88.5	107.4	(86.9-131.3)
<b><u>Lung and Bronchus</u></b>									
Male	13	13.4	96.8	(51.5-165.5)					
Female	16	12.6	127.1	(72.6-206.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	60	43.1	139.1	(106.1-179.0)	Male	25	28.9	86.4	(55.9-127.5)
Female	21	18.6	112.9	(69.9-172.6)	Female	25	25.3	99.0	(64.0-146.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	8.7	92.2	(39.7-181.7)	Male	6	7.2	83.4	(30.4-181.5)
Female	10	8.0	125.1	(59.9-230.0)	Female	9	6.6	135.5	(61.8-257.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	21	25.3	83.0	(51.3-126.8)
Female	196	177.8	110.3	(95.4-126.8)	Female	19	23.4	81.0	(48.8-126.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.8	87.8	(32.1-191.1)	Male	14	17.6	79.4	(43.4-133.2)
<b><u>Colon / Rectum</u></b>					Female	12	9.1	132.5	(68.4-231.5)
Male	70	53.0	132.0	(102.9-166.8)	<b><u>Ovary</u></b>				
Female	53	63.1	83.9	(62.9-109.8)	Female	11	17.4	63.2	(31.5-113.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	11.2	133.3	(74.6-219.9)	Male	22	14.0	157.3	(98.5-238.1)
Female	3	3.8	nc	(nc-nc)	Female	15	17.9	83.7	(46.8-138.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.9	nc	(nc-nc)	Male	182	160.2	113.6	(97.7-131.4)
Female	4	3.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	10.1	79.3	(34.1-156.2)
Male	32	23.6	135.5	(92.6-191.2)	Female	12	7.4	161.8	(83.5-282.7)
Female	11	15.0	73.3	(36.6-131.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	6.6	167.4	(83.4-299.5)
Male	11	6.5	168.4	(83.9-301.3)	<b><u>Thyroid</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	9	9.7	92.6	(42.2-175.7)
<b><u>Leukemia</u></b>					Female	39	31.2	124.8	(88.8-170.7)
Male	15	16.3	92.0	(51.4-151.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	14.0	64.3	(29.3-122.0)	Female	44	38.9	113.1	(82.2-151.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	12.6	118.8	(66.5-196.0)	Male	657	583.4	112.6	(104.2-121.6)
Female	3	4.9	nc	(nc-nc)	Female	675	638.7	105.7	(97.9-114.0)
<b><u>Lung and Bronchus</u></b>									
Male	80	78.5	101.9	(80.8-126.9)					
Female	99	90.2	109.7	(89.2-133.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	17.7	192.0	(132.9-268.2)	Male	23	12.5	184.0	(116.6-276.0)
Female	15	8.0	187.8	(105.0-309.8)	Female	15	10.9	137.6	(76.9-226.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.0	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	6	3.5	169.6	(61.9-369.1)	Female	5	2.8	176.6	(56.9-412.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.5	nc	(nc-nc)	Male	21	11.1	189.4	(117.2-289.5)
Female	82	78.6	104.4	(83.0-129.6)	Female	7	10.1	69.3	(27.8-142.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.1	nc	(nc-nc)	Male	10	8.1	123.1	(58.9-226.4)
<b><u>Colon / Rectum</u></b>					Female	2	4.0	nc	(nc-nc)
Male	39	22.2	175.8	(125.0-240.3)	<b><u>Ovary</u></b>				
Female	30	26.4	113.6	(76.6-162.2)	Female	12	7.7	155.9	(80.5-272.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	5.0	238.9	(123.3-417.4)	Male	7	5.9	119.5	(47.9-246.2)
Female	4	1.6	nc	(nc-nc)	Female	8	7.6	105.6	(45.5-208.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	93	74.2	125.4	(101.2-153.6)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	4.2	189.0	(81.4-372.4)
Male	19	10.5	181.3	(109.1-283.1)	Female	1	3.2	nc	(nc-nc)
Female	4	6.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.0	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	7	4.4	157.6	(63.2-324.8)
<b><u>Leukemia</u></b>					Female	18	13.9	129.5	(76.7-204.7)
Male	12	7.1	169.8	(87.6-296.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	6.0	132.7	(57.1-261.5)	Female	21	18.0	116.8	(72.3-178.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	5.7	123.1	(49.3-253.6)	Male	385	256.0	150.4	(135.7-166.2)
Female	4	2.1	nc	(nc-nc)	Female	322	277.9	115.9	(103.6-129.3)
<b><u>Lung and Bronchus</u></b>									
Male	50	33.2	150.6	(111.8-198.6)					
Female	56	38.5	145.5	(109.9-189.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	7.8	63.8	(20.6-148.9)
Female	0	0.0	nc	(nc-nc)	Female	6	4.8	125.0	(45.7-272.2)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.9	114.4	(52.2-217.2)	Male	7	6.0	116.8	(46.8-240.6)
Female	4	3.4	nc	(nc-nc)	Female	6	4.7	129.0	(47.1-280.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	5	1.4	360.4	(116.2-841.1)
Female	2	1.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	5.1	97.5	(31.4-227.5)
Female	41	34.6	118.6	(85.1-161.0)	Female	7	4.4	159.6	(63.9-328.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.7	nc	(nc-nc)
Male	8	10.2	78.1	(33.6-153.9)	<b><u>Ovary</u></b>				
Female	8	11.3	70.8	(30.5-139.5)	Female	2	3.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	42	33.1	126.8	(91.4-171.4)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.8	121.7	(48.7-250.7)
Male	1	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.6	nc	(nc-nc)	Female	8	7.8	102.4	(44.1-201.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	130	117.2	111.0	(92.7-131.8)
Female	1	0.9	nc	(nc-nc)	Female	135	121.1	111.5	(93.5-132.0)
<b><u>Lung and Bronchus</u></b>									
Male	16	14.9	107.1	(61.2-173.9)					
Female	24	17.7	135.2	(86.6-201.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	23.8	202.1	(149.0-267.9)	Male	10	17.0	58.8	(28.2-108.2)
Female	9	10.3	87.2	(39.8-165.5)	Female	11	15.3	72.0	(35.9-128.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	5.3	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	5	4.8	105.0	(33.8-245.1)	Female	6	3.7	161.3	(58.9-351.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	10	14.8	67.5	(32.3-124.1)
Female	84	105.7	79.5	(63.4-98.4)	Female	17	13.4	127.0	(73.9-203.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.3	162.1	(64.9-334.0)	Male	8	10.8	74.3	(32.0-146.3)
<b><u>Colon / Rectum</u></b>					Female	6	5.3	113.6	(41.5-247.3)
Male	36	30.2	119.0	(83.4-164.8)	<b><u>Ovary</u></b>				
Female	34	35.5	95.7	(66.3-133.7)	Female	8	10.3	77.7	(33.5-153.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.6	90.8	(33.2-197.6)	Male	10	7.8	127.9	(61.2-235.3)
Female	2	2.1	nc	(nc-nc)	Female	9	9.9	91.0	(41.5-172.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	128	96.2	133.0	(111.0-158.2)
Female	0	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	5.7	139.6	(60.1-275.0)
Male	19	14.2	134.2	(80.7-209.5)	Female	1	4.1	nc	(nc-nc)
Female	7	8.6	81.0	(32.4-166.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	4.6	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	6	6.2	96.9	(35.4-210.9)
<b><u>Leukemia</u></b>					Female	18	19.9	90.5	(53.6-143.0)
Male	12	9.3	128.4	(66.2-224.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	8.1	98.7	(42.5-194.5)	Female	12	23.5	51.1	(26.4-89.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.6	nc	(nc-nc)	Male	405	341.1	118.8	(107.5-130.9)
Female	2	2.8	nc	(nc-nc)	Female	326	371.4	87.8	(78.5-97.8)
<b><u>Lung and Bronchus</u></b>									
Male	60	44.3	135.3	(103.3-174.2)					
Female	54	50.1	107.9	(81.0-140.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	14.6	137.2	(83.8-211.9)	Male	9	9.7	92.4	(42.2-175.4)
Female	14	6.5	217.0	(118.6-364.2)	Female	1	8.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.8	177.9	(57.3-415.2)	Male	3	2.4	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	8.5	129.8	(64.7-232.3)
Female	58	62.8	92.4	(70.2-119.5)	Female	2	8.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.4	nc	(nc-nc)	Male	5	6.1	81.9	(26.4-191.0)
<b><u>Colon / Rectum</u></b>					Female	3	3.2	nc	(nc-nc)
Male	19	17.7	107.2	(64.5-167.4)	<b><u>Ovary</u></b>				
Female	14	21.6	64.9	(35.4-108.8)	Female	6	6.1	98.5	(36.0-214.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.9	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	11	6.2	178.3	(88.9-319.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	51	57.2	89.1	(66.4-117.2)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.4	147.1	(47.4-343.3)
Male	9	8.1	111.3	(50.8-211.3)	Female	3	2.5	nc	(nc-nc)
Female	9	5.2	172.0	(78.5-326.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.0	nc	(nc-nc)
Male	5	2.3	216.3	(69.7-504.8)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	10.9	55.2	(20.2-120.2)
Male	4	5.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.8	nc	(nc-nc)	Female	15	14.2	105.9	(59.2-174.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.4	nc	(nc-nc)	Male	210	199.7	105.1	(91.4-120.4)
Female	1	1.7	nc	(nc-nc)	Female	218	222.9	97.8	(85.3-111.7)
<b><u>Lung and Bronchus</u></b>									
Male	30	26.9	111.6	(75.3-159.4)					
Female	42	31.4	133.7	(96.3-180.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	6.6	120.9	(52.1-238.2)	Male	8	5.0	159.6	(68.7-314.5)
Female	4	2.7	nc	(nc-nc)	Female	9	4.4	203.9	(93.1-387.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	39	32.1	121.6	(86.5-166.3)	Female	3	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	6	3.3	180.2	(65.8-392.3)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	11	8.8	125.6	(62.6-224.8)	<b><u>Ovary</u></b>				
Female	9	9.0	99.6	(45.4-189.1)	Female	2	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	34	29.9	113.7	(78.7-158.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	6.1	165.0	(79.0-303.4)
Male	4	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	2.1	233.3	(75.2-544.4)	Female	4	7.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	119	100.9	118.0	(97.7-141.2)
Female	0	0.8	nc	(nc-nc)	Female	118	107.1	110.1	(91.2-131.9)
<b><u>Lung and Bronchus</u></b>									
Male	13	13.0	99.8	(53.1-170.7)					
Female	15	14.8	101.2	(56.6-166.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	5	10.8	46.4	(15.0-108.3)	Female	1	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	3.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	8.8	102.6	(46.8-194.9)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	23	31.2	73.7	(46.7-110.6)
Female	0	0.3	nc	(nc-nc)	Female	26	35.5	73.2	(47.8-107.3)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.8	nc	(nc-nc)					
Female	7	4.7	148.4	(59.4-305.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	30.7	91.3	(60.7-132.0)	Male	29	19.4	149.5	(100.1-214.7)
Female	5	11.6	43.2	(13.9-100.8)	Female	25	16.0	156.5	(101.2-231.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.6	nc	(nc-nc)	Male	8	5.0	159.6	(68.7-314.5)
Female	5	5.0	100.1	(32.2-233.5)	Female	11	4.2	261.0	(130.1-467.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	16	17.2	93.2	(53.2-151.4)
Female	127	117.8	107.8	(89.9-128.3)	Female	20	14.9	134.2	(81.9-207.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.3	117.4	(37.8-273.9)	Male	10	11.8	84.7	(40.5-155.8)
<b><u>Colon / Rectum</u></b>					Female	4	5.9	nc	(nc-nc)
Male	35	37.0	94.7	(66.0-131.7)	<b><u>Ovary</u></b>				
Female	42	38.5	109.1	(78.6-147.4)	Female	18	11.4	158.3	(93.8-250.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.8	63.9	(20.6-149.2)	Male	11	9.8	112.4	(56.0-201.2)
Female	4	2.4	nc	(nc-nc)	Female	8	11.0	72.7	(31.3-143.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	125	111.7	111.9	(93.1-133.3)
Female	2	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	7.1	nc	(nc-nc)
Male	14	15.9	88.0	(48.1-147.6)	Female	5	4.4	114.6	(36.9-267.4)
Female	11	9.9	111.2	(55.4-199.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.4	149.2	(48.1-348.1)
Male	3	4.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	14	6.0	234.4	(128.0-393.3)
<b><u>Leukemia</u></b>					Female	21	19.8	105.9	(65.5-161.9)
Male	11	11.2	98.0	(48.9-175.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.5	105.3	(48.0-199.9)	Female	27	27.0	100.0	(65.9-145.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	8.6	104.1	(47.5-197.6)	Male	387	402.5	96.2	(86.8-106.2)
Female	3	3.2	nc	(nc-nc)	Female	440	411.3	107.0	(97.2-117.4)
<b><u>Lung and Bronchus</u></b>									
Male	32	55.3	57.9	(39.6-81.7)					
Female	59	59.5	99.1	(75.4-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	4	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	6	0.7	838.0	(306.0-1824.0)
Female	0	0.0	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	0.1	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	9.4	nc	(nc-nc)	Male	11	6.7	163.2	(81.4-292.1)
Female	4	2.9	nc	(nc-nc)	Female	6	4.8	124.9	(45.6-271.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.0	249.4	(80.4-581.9)	Male	1	1.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	30	33.8	88.6	(59.8-126.5)	Female	4	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.4	nc	(nc-nc)	Male	8	4.4	179.9	(77.5-354.5)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	11	12.0	91.4	(45.6-163.6)	<b><u>Ovary</u></b>				
Female	12	9.9	120.9	(62.4-211.3)	Female	4	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	6	3.1	191.6	(70.0-417.0)
Female	1	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	45	40.0	112.5	(82.1-150.5)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.3	nc	(nc-nc)
Male	6	5.8	103.7	(37.9-225.8)	Female	1	1.1	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.4	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	6.5	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.3	nc	(nc-nc)	Female	4	7.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	144	136.7	105.3	(88.8-124.0)
Female	0	0.8	nc	(nc-nc)	Female	109	113.8	95.8	(78.6-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	18	17.7	101.4	(60.1-160.3)					
Female	16	15.4	103.7	(59.2-168.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.8	74.0	(31.8-145.7)	Male	3	7.0	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	41	37.0	110.8	(79.5-150.3)	Female	5	4.7	107.2	(34.6-250.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	0	4.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.8	nc	(nc-nc)
Male	15	13.1	114.5	(64.1-188.9)	<b><u>Ovary</u></b>				
Female	13	11.8	109.8	(58.4-187.7)	Female	4	3.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	2.9	208.9	(76.3-454.7)	Male	4	3.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	29	41.7	69.5	(46.6-99.9)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	5	5.8	86.6	(27.9-202.1)	Female	0	1.3	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	6.3	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.6	nc	(nc-nc)	Female	7	8.7	80.3	(32.2-165.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.2	nc	(nc-nc)	Male	112	145.5	77.0	(63.4-92.6)
Female	0	1.0	nc	(nc-nc)	Female	119	128.8	92.4	(76.6-110.6)
<b><u>Lung and Bronchus</u></b>									
Male	19	19.8	96.1	(57.8-150.0)					
Female	19	18.5	102.8	(61.9-160.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	5	4.3	116.3	(37.5-271.4)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	6.1	130.7	(56.3-257.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	18	19.5	92.2	(54.6-145.8)
Female	0	0.1	nc	(nc-nc)	Female	9	15.1	59.4	(27.1-112.8)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.8	nc	(nc-nc)					
Female	0	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	10.9	118.8	(63.2-203.1)
Female	0	0.1	nc	(nc-nc)	Female	9	8.4	107.4	(49.0-203.8)
<b><u>Lung and Bronchus</u></b>									
Male	4	1.4	nc	(nc-nc)					
Female	3	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.4	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	6.5	138.8	(63.3-263.4)	Male	10	4.0	252.9	(121.1-465.0)
Female	3	1.9	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	20	17.9	111.7	(68.2-172.6)	Female	0	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	6	7.6	79.0	(28.9-172.0)	<b><u>Ovary</u></b>				
Female	7	6.6	105.9	(42.4-218.3)	Female	3	1.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	22	25.0	88.0	(55.1-133.3)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.5	nc	(nc-nc)
Male	0	3.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.7	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.4	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	85	84.8	100.3	(80.1-124.0)
Female	1	0.5	nc	(nc-nc)	Female	64	64.3	99.5	(76.6-127.1)
<b><u>Lung and Bronchus</u></b>									
Male	11	11.9	92.6	(46.2-165.7)					
Female	14	9.2	153.0	(83.6-256.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	10.0	99.7	(47.7-183.4)	Male	22	7.3	301.8	(189.1-457.0)
Female	6	3.5	172.3	(62.9-375.0)	Female	8	5.5	146.5	(63.1-288.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	6.3	126.7	(54.5-249.6)
Female	46	38.0	121.2	(88.7-161.6)	Female	5	4.6	108.9	(35.1-254.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	16	12.7	125.6	(71.8-204.0)	<b><u>Ovary</u></b>				
Female	17	11.8	144.6	(84.2-231.5)	Female	7	3.7	191.3	(76.6-394.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	5	3.3	150.1	(48.4-350.3)
Female	4	0.7	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	78	41.9	186.0	(147.1-232.2)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.4	nc	(nc-nc)
Male	2	6.1	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	5	2.7	186.6	(60.1-435.5)
<b><u>Leukemia</u></b>					Female	1	7.4	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.8	nc	(nc-nc)	Female	7	8.5	82.0	(32.8-168.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	195	145.9	133.7	(115.6-153.8)
Female	0	1.0	nc	(nc-nc)	Female	139	130.5	106.5	(89.5-125.7)
<b><u>Lung and Bronchus</u></b>									
Male	16	18.9	84.9	(48.5-137.8)					
Female	12	17.5	68.4	(35.3-119.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	35.7	92.3	(63.5-129.7)	Male	30	23.4	128.5	(86.7-183.4)
Female	17	12.6	135.4	(78.9-216.9)	Female	17	18.4	92.5	(53.8-148.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	15	6.8	219.3	(122.6-361.7)	Male	8	5.9	136.2	(58.7-268.5)
Female	6	5.6	106.3	(38.8-231.3)	Female	3	4.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	19	20.5	92.8	(55.8-144.9)
Female	154	133.2	115.7	(98.1-135.4)	Female	16	16.3	98.3	(56.2-159.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.2	nc	(nc-nc)	Male	11	14.1	77.8	(38.8-139.1)
<b><u>Colon / Rectum</u></b>					Female	13	6.5	199.5	(106.1-341.2)
Male	52	43.5	119.6	(89.3-156.8)	<b><u>Ovary</u></b>				
Female	44	41.9	104.9	(76.2-140.9)	Female	18	12.6	142.6	(84.5-225.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	9.2	54.2	(17.5-126.5)	Male	15	11.5	130.6	(73.0-215.4)
Female	2	2.6	nc	(nc-nc)	Female	13	11.9	109.0	(58.0-186.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	146	132.9	109.9	(92.8-129.2)
Female	2	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	8.3	108.0	(49.3-205.0)
Male	18	19.0	94.8	(56.1-149.8)	Female	4	4.8	nc	(nc-nc)
Female	7	10.9	64.2	(25.7-132.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	5.0	nc	(nc-nc)
Male	5	5.4	92.8	(29.9-216.6)	<b><u>Thyroid</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	12	7.6	158.2	(81.7-276.4)
<b><u>Leukemia</u></b>					Female	30	24.0	125.0	(84.3-178.4)
Male	11	13.3	82.5	(41.1-147.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	9.4	160.0	(89.5-263.9)	Female	21	30.0	69.9	(43.3-106.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	10.1	49.4	(15.9-115.4)	Male	501	477.9	104.8	(95.9-114.4)
Female	0	3.4	nc	(nc-nc)	Female	506	457.7	110.6	(101.1-120.6)
<b><u>Lung and Bronchus</u></b>									
Male	50	64.5	77.5	(57.6-102.2)					
Female	69	63.7	108.3	(84.2-137.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	35.5	107.1	(75.8-147.0)	Male	34	21.9	155.4	(107.6-217.2)
Female	12	13.8	86.8	(44.8-151.7)	Female	25	18.0	139.2	(90.1-205.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	6.2	nc	(nc-nc)	Male	9	5.8	156.2	(71.3-296.6)
Female	5	5.7	87.6	(28.2-204.5)	Female	2	5.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	25	19.5	128.3	(83.0-189.4)
Female	166	133.8	124.0	(105.9-144.4)	Female	27	17.3	156.4	(103.1-227.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.8	124.7	(45.5-271.4)	Male	12	12.9	93.2	(48.1-162.7)
<b><u>Colon / Rectum</u></b>					Female	5	6.7	74.3	(23.9-173.4)
Male	35	42.5	82.4	(57.4-114.7)	<b><u>Ovary</u></b>				
Female	42	47.2	89.0	(64.1-120.3)	Female	9	13.0	69.3	(31.6-131.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	8.6	92.9	(40.0-183.1)	Male	11	11.2	97.9	(48.8-175.1)
Female	3	2.8	nc	(nc-nc)	Female	18	13.3	135.2	(80.1-213.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	159	120.0	132.5	(112.7-154.7)
Female	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.1	61.4	(19.8-143.4)
Male	13	17.5	74.3	(39.5-127.0)	Female	4	5.5	nc	(nc-nc)
Female	5	11.0	45.3	(14.6-105.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.6	nc	(nc-nc)
Male	6	5.0	120.9	(44.1-263.2)	<b><u>Thyroid</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	13	6.5	198.8	(105.8-340.0)
<b><u>Leukemia</u></b>					Female	36	21.5	167.6	(117.4-232.1)
Male	13	12.9	100.5	(53.5-171.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	10.3	107.2	(53.4-191.8)	Female	31	29.6	104.8	(71.2-148.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	9.4	53.1	(17.1-123.9)	Male	472	449.3	105.1	(95.8-115.0)
Female	2	3.7	nc	(nc-nc)	Female	508	472.5	107.5	(98.4-117.3)
<b><u>Lung and Bronchus</u></b>									
Male	40	62.2	64.3	(45.9-87.5)					
Female	55	66.1	83.1	(62.6-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	5.6	125.3	(50.2-258.1)
Female	0	0.0	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.7	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	107	92.0	116.2	(95.3-140.5)	Male	39	59.5	65.6	(46.6-89.6)
Female	42	40.6	103.6	(74.6-140.0)	Female	20	54.2	36.9	(22.5-57.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	17.8	90.0	(51.4-146.2)	Male	18	15.0	120.1	(71.2-189.9)
Female	27	17.3	156.2	(102.9-227.2)	Female	12	14.4	83.1	(42.9-145.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	53	52.1	101.7	(76.2-133.0)
Female	320	379.7	84.3	(75.3-94.0)	Female	44	50.9	86.4	(62.8-116.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	31	14.5	214.3	(145.6-304.2)	Male	54	34.9	154.6	(116.1-201.7)
<b><u>Colon / Rectum</u></b>					Female	39	19.6	199.0	(141.5-272.0)
Male	135	109.5	123.3	(103.3-145.9)	<b><u>Ovary</u></b>				
Female	141	135.9	103.7	(87.3-122.3)	Female	30	37.5	79.9	(53.9-114.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	36	23.3	154.4	(108.1-213.7)	Male	32	29.4	108.7	(74.3-153.5)
Female	7	8.3	84.3	(33.8-173.7)	Female	43	39.0	110.3	(79.9-148.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	9	8.3	108.4	(49.5-205.8)	Male	408	333.8	122.2	(110.7-134.7)
Female	7	7.2	97.0	(38.8-199.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	28	21.1	132.6	(88.1-191.6)
Male	66	47.9	137.9	(106.7-175.5)	Female	20	16.0	125.4	(76.5-193.6)
Female	43	32.6	131.8	(95.4-177.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	13.9	86.3	(44.5-150.8)
Male	19	13.5	141.0	(84.8-220.1)	<b><u>Thyroid</u></b>				
Female	11	4.5	244.9	(122.1-438.1)	Male	17	19.2	88.5	(51.5-141.6)
<b><u>Leukemia</u></b>					Female	46	66.1	69.5	(50.9-92.8)
Male	36	34.2	105.2	(73.6-145.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	24	30.3	79.3	(50.8-118.0)	Female	84	85.0	98.9	(78.9-122.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	48	25.4	189.1	(139.4-250.7)	Male	1466	1214.6	120.7	(114.6-127.0)
Female	13	10.7	121.0	(64.4-207.0)	Female	1320	1379.0	95.7	(90.6-101.0)
<b><u>Lung and Bronchus</u></b>									
Male	233	166.5	139.9	(122.5-159.1)					
Female	192	198.9	96.6	(83.4-111.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	7	14.0	49.9	(20.0-102.8)
Female	0	0.1	nc	(nc-nc)	Female	9	14.1	63.6	(29.0-120.8)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.7	nc	(nc-nc)					
Female	1	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	6	6.8	88.5	(32.3-192.6)	Female	2	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	15	8.7	173.0	(96.8-285.4)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	3	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.2	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	35	30.8	113.5	(79.0-157.9)
Female	0	0.2	nc	(nc-nc)	Female	18	23.5	76.5	(45.3-120.8)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.2	nc	(nc-nc)					
Female	3	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	14.7	61.2	(27.9-116.3)
Female	0	0.1	nc	(nc-nc)	Female	9	15.0	60.2	(27.5-114.2)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.0	nc	(nc-nc)					
Female	2	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;